Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1563056rdf:typepubmed:Citationlld:pubmed
pubmed-article:1563056lifeskim:mentionsumls-concept:C0006400lld:lifeskim
pubmed-article:1563056lifeskim:mentionsumls-concept:C0039629lld:lifeskim
pubmed-article:1563056lifeskim:mentionsumls-concept:C0002928lld:lifeskim
pubmed-article:1563056lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:1563056lifeskim:mentionsumls-concept:C0037633lld:lifeskim
pubmed-article:1563056lifeskim:mentionsumls-concept:C0549178lld:lifeskim
pubmed-article:1563056pubmed:issue4lld:pubmed
pubmed-article:1563056pubmed:dateCreated1992-5-21lld:pubmed
pubmed-article:1563056pubmed:abstractTextThe aim of this study was to compare two equipotent solutions of hyperbaric bupivacaine and tetracaine in 30 elderly patients undergoing elective hip surgery under continuous spinal anaesthesia. With the patient in the supine position, 2 ml (8 mg) of either hyperbaric solution (density 1.030) were administered in a double-blind and randomized fashion. The median maximum sensory and temperature discrimination levels (T5 and T4) were similar with both solutions. The duration of analgesia was not different (114 +/- 23 min for bupivacaine and 125 +/- 35 min for tetracaine). Thirteen out of fifteen patients receiving bupivacaine and all 15 patients receiving tetracaine had complete motor blockade. The haemodynamic changes and vasopressor requirements were comparable. The plasma catecholamine levels measured at four different times remained unchanged and were not different between the two groups at any time. The authors conclude that, during continuous spinal anaesthesia, equipotent hyperbaric solutions of bupivacaine and tetracaine have similar anaesthetic and haemodynamic effects.lld:pubmed
pubmed-article:1563056pubmed:languageenglld:pubmed
pubmed-article:1563056pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1563056pubmed:citationSubsetIMlld:pubmed
pubmed-article:1563056pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1563056pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1563056pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1563056pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1563056pubmed:statusMEDLINElld:pubmed
pubmed-article:1563056pubmed:monthAprlld:pubmed
pubmed-article:1563056pubmed:issn0832-610Xlld:pubmed
pubmed-article:1563056pubmed:authorpubmed-author:GamulinZZlld:pubmed
pubmed-article:1563056pubmed:authorpubmed-author:ForsterAAlld:pubmed
pubmed-article:1563056pubmed:authorpubmed-author:FathiMMlld:pubmed
pubmed-article:1563056pubmed:authorpubmed-author:SalvatMMlld:pubmed
pubmed-article:1563056pubmed:authorpubmed-author:Van GesselE...lld:pubmed
pubmed-article:1563056pubmed:authorpubmed-author:MiegeBBlld:pubmed
pubmed-article:1563056pubmed:issnTypePrintlld:pubmed
pubmed-article:1563056pubmed:volume39lld:pubmed
pubmed-article:1563056pubmed:ownerNLMlld:pubmed
pubmed-article:1563056pubmed:authorsCompleteYlld:pubmed
pubmed-article:1563056pubmed:pagination323-9lld:pubmed
pubmed-article:1563056pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:meshHeadingpubmed-meshheading:1563056-...lld:pubmed
pubmed-article:1563056pubmed:year1992lld:pubmed
pubmed-article:1563056pubmed:articleTitleComparison of hyperbaric solutions of bupivacaine and tetracaine during continuous spinal anaesthesia.lld:pubmed
pubmed-article:1563056pubmed:affiliationDepartment of Anaesthesiology, University Hospital, Geneva, Switzerland.lld:pubmed
pubmed-article:1563056pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1563056pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1563056pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1563056pubmed:publicationTypeRandomized Controlled Triallld:pubmed